European Players Wake Up to Japanese Opportunities

European biotech companies have historically shied away from regional transactions in Japan, instead lumping Japanese rights into global deals with more familiar Western counterparts. But some recent deals indicate that they're beginning to recognize the significant value in separating out Japanese rights. Particularly since nowadays, licensing in Japan needn't be any more challenging than it is anywhere else.